Sector News

SK bioscience and Thailand’s GPO enter MoU to boost vaccine response

July 7, 2023
Life sciences

South Korea-based SK bioscience and the Thailand state-owned pharmaceutical company the Government Pharmaceutical Organisation (GPO) have entered a memorandum of understanding (MoU) to bolster vaccine infrastructure in Thailand.

The deal will enhance the country’s pandemic response system, aiming to produce Thailand’s vaccines locally. It will then be expanded to the wider southeast Asian region.

The two companies will support vaccine development and manufacturing capabilities in Thailand, working together closely in the mid-to-long-term to support the country as a vaccine hub in southeast Asia.

SK bioscience will transfer its cell culture-based influenza vaccine’s production and manufacturing technology to the GPO’s facility.

Following this technology transfer, SK bioscience will provide the vaccine’s processes to the Thai company, which will seek marketing authorisation from the regulators.

The vaccines produced will be used for the national vaccination drive in Thailand.

GPO managing director Dr Mingkwan Suphannaphong stated: “A MoU-signing ceremony between GPO and SK bioscience today substantially contributes to a collaboration on manufacturing the cell-culture based influenza vaccine locally in Thailand, namely the trivalent and quadrivalent inactivated influenza vaccines.

“The drug substance bulk produced by SK will be initially delivered to GPO prior to making the drug products.”

In June 2023, SK bioscience and the Peter Doherty Institute for Infection and Immunity entered a research partnership to develop a next-generation influenza vaccine.

Source: pharmaceutical-technology.com

 

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach